BioSpace News Archive

Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that it has been selected for addition to the NASDAQ Biotechnology Index, effective prior to market open on Monday, December 21, 2020.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that John Maxwell, Senior Vice President, Chief Financial Officer (CFO) of the Company,

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, has prioritised the recommencement of the process of scaling up the manufacturing of its lead product candidate eftilagimod alpha (“efti” or “IMP321”). This follows the very encouraging interim results Immutep announced from its efti clinical trials at SITC (10 Nove

Medtronic plc (NYSE: MDT) announced that the U.S. Food and Drug Administration (FDA) has cleared the use of navigated interbody and Midas Rex™ high speed drills with the Mazor™ Robotic Guidance System earlier than originally anticipated.

Emedgene, a leading precision medicine intelligence company, announces a non-exclusive partnership with Illumina Inc. and the integration of automated interpretation into Illumina’s TruSight™ Software Suite for rare genetic diseases

Pall Corporation, a global leader in filtration, separation and purification, announced a strategic partnership with Single Use Support GmbH, a leading provider of an innovative, end-to-end solution for safe handling of biologics from bulk manufacturing to fill finish

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“the “Company”) today announced that on December 15, 2020, it received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq’s minimum bid price requirement and is in compliance with all applicable listing standards.

Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Howard K. Surks, M.D., as chief scientific officer and head, translational medicine

Sartorius recently recognized startup company MyoGene Bio at the QB3 Pitch Summit, a competition showcasing promising new life science companies. This award provides the company with a $25,000 voucher that they can use for the purchase of any Sartorius products and services to support their development of a gene therapy for Duchenne muscular dystrophy (DMD). MyoGene Bio’s MyoDys 45-55 gene editing therapy uses CRISPR

IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a collaboration with Servier, an independent global pharmaceutical company, to reinvent their R&D clinical development processes and support their long-term R&D success. Servier has ambitious plans for growth a